Business Description
Rezolute Inc
NAICS : 325412
SIC : 2834
ISIN : US76200L3096
Total Employee Number:
71Description
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 108.25 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 19.5 | |||||
3-Year EPS without NRI Growth Rate | 26.2 | |||||
3-Year FCF Growth Rate | 23.5 | |||||
3-Year Book Growth Rate | -25.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.04 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 78.42 | |||||
9-Day RSI | 74.5 | |||||
14-Day RSI | 71.8 | |||||
3-1 Month Momentum % | 8.2 | |||||
6-1 Month Momentum % | 39.83 | |||||
12-1 Month Momentum % | -26.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 15.84 | |||||
Quick Ratio | 15.84 | |||||
Cash Ratio | 15.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -37.3 | |||||
Shareholder Yield % | 0.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -63.99 | |||||
ROA % | -58.79 | |||||
ROIC % | -1295.68 | |||||
3-Year ROIIC % | -561.16 | |||||
ROC (Joel Greenblatt) % | -6875.81 | |||||
ROCE % | -67.84 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.27 | |||||
Price-to-Tangible-Book | 4.28 | |||||
EV-to-EBIT | -4.35 | |||||
EV-to-EBITDA | -4.35 | |||||
EV-to-Forward-Revenue | 21.49 | |||||
EV-to-FCF | -5.17 | |||||
| Price-to-Net-Current-Asset-Value | 4.39 | |||||
| Price-to-Net-Cash | 4.47 | |||||
Earnings Yield (Greenblatt) % | -22.99 | |||||
FCF Yield % | -14.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RZLT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rezolute Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.82 | ||
| Beta | 2.0872 | ||
| 3-Year Sharpe Ratio | 0.66 | ||
| 3-Year Sortino Ratio | 1.05 | ||
| Volatility % | 115.87 | ||
| 14-Day RSI | 71.8 | ||
| 14-Day ATR ($) | 0.334687 | ||
| 20-Day SMA ($) | 4.556 | ||
| 12-1 Month Momentum % | -26.01 | ||
| 52-Week Range ($) | 1.07 - 11.4565 | ||
| Shares Outstanding (Mil) | 96.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rezolute Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rezolute Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2027 | 2026-11-19 15:00 | In 142 days | ||
| First quarter earnings results for 2027 | 2026-11-06 | In 128 days | ||
| Annual report for 2026 | 2026-09-17 | In 78 days | ||
| Fourth quarter earnings results for 2026 | 2026-09-17 | In 78 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 15:45 | 4.58 (+4.81%) | ||
| H.C. Wainwright 4(th) Annual BioConnect Investor Conference | 2026-05-19 | 3.24 (-3.28%) | ||
| Third quarter earnings results for 2026 | 2026-05-12 16:05 | 3.17 (-3.06%) | ||
| Second quarter earnings results for 2026 | 2026-02-12 | 3.37 (+10.13%) | ||
| sunRIZE Topline Data Conference Call | 2025-12-11 08:30 | 10.94 (+10.39%) | ||
| General meeting for 2026 | 2025-11-19 15:00 | 10.16 (+0.30%) |
Show
Entries
Rezolute Inc Frequently Asked Questions
What is Rezolute Inc(RZLT)'s stock price today?
The current price of RZLT is $5.18. The 52 week high of RZLT is $11.46 and 52 week low is $1.07.
When is next earnings date of Rezolute Inc(RZLT)?
The next earnings date of Rezolute Inc(RZLT) is 2026-09-17 Est..
Does Rezolute Inc(RZLT) pay dividends? If so, how much?
Rezolute Inc(RZLT) does not pay dividend.
Guru Commentaries on NAS:RZLT
No articles.
Press Release
Articles on Rezolute Inc
No articles.
Headlines
See More- 1
Jun 04, 2026
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Benzinga • 6:30am
Jun 03, 2026
Rezolute upgraded at Citizens after late-stage trial data for lead asset
Seeking Alpha • 10:30am
Jun 02, 2026
Rezolute rises after late-stage trial update
Seeking Alpha • 11:24am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers